Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J4IP
|
|||
| Drug Name |
PMID26560530-Compound-31
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Aston University
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H31N2O6S+
|
|||
| Canonical SMILES |
C[S+](C)CC(=O)CCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
|
|||
| InChI |
1S/C25H30N2O6S/c1-34(2)17-20(28)13-14-21(24(30)31)26-23(29)22(15-18-9-5-3-6-10-18)27-25(32)33-16-19-11-7-4-8-12-19/h3-12,21-22H,13-17H2,1-2H3,(H2-,26,27,29,30,31,32)/p+1/t21-,22-/m0/s1
|
|||
| InChIKey |
MQKDBWQFOOQINN-VXKWHMMOSA-O
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.